gene therapy
Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases
Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Pfizer Announces Additional Layoffs in North Carolina Following DMD Trial Setback
Pfizer layoffs, North Carolina, Duchenne muscular dystrophy (DMD), gene therapy trial failure, cost-cutting measures
Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies
Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments
Sangamo Therapeutics Aligns with FDA on Accelerated Approval Pathway for ST-920 Gene Therapy in Fabry Disease
Sangamo Therapeutics, FDA, Accelerated Approval Pathway, ST-920, Fabry Disease, Gene Therapy, BLA Submission
Sangamo Therapeutics Fast-Tracks Fabry Gene Therapy with FDA Accelerated Approval Pathway
Sangamo Therapeutics, Fabry disease, gene therapy, isaralgagene civaparvovec, FDA, accelerated approval pathway, ST-920, STAAR study
MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial
MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production
MeiraGTx Announces Positive Phase 2 Data for AAV-GAD Gene Therapy in Parkinson’s Disease, Paving Way for Phase 3 Trial
MeiraGTx, AAV-GAD, Gene Therapy, Parkinson’s Disease, Phase 2 Trial, Phase 3 Trial, Neurodegenerative Disorders, Genetic Medicine
Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months
Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI
Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership
AI drug discovery, Basecamp Research, Broad Institute, David R. Liu, Biotechnology, Gene therapy, Artificial intelligence in biology